First-in-human phase I study of givastomig, a novel Claudin 18.2/4-1BB bispecific antibody in advanced solid tumors

被引：1

作者：

Ku, G. ^{[1
]}

Shen, L. ^{[2
]}

Klempner, S. J. ^{[3
]}

Pan, H. ^{[4
]}

Kratz, J. ^{[5
]}

Liang, X. ^{[6
]}

Deng, Y. ^{[7
]}

Kim, S. ^{[8
]}

Wang, Z. ^{[9
]}

Feller, L. ^{[10
]}

Powderly, J. ^{[11
]}

Dayyani, F. ^{[12
]}

Schneider, R. E. ^{[13
]}

Girda, E. ^{[14
]}

Berlin, J. D. ^{[15
]}

Spencer, K. ^{[16
]}

Nguyen, M. T. ^{[17
]}

Wang, V. ^{[17
]}

Xu, C. ^{[17
]}

Zhu, A. ^{[18
]}

机构：

[1] MSKCC Mem Sloan Kettering Canc Ctr, Dept Med, Gastrointestinal Oncol Serv, New York, NY USA

[2] Peking Univ Canc Hosp & Inst, GI Oncol Dept, Beijing, Peoples R China

[3] MGH Massachusetts Gen Hosp, Med Oncol Dept, Boston, MA USA

[4] Zhejiang Univ, Sir Run Run Run Shaw Hosp, Med, Sch Med, Hangzhou, Zhejiang, Peoples R China

[5] Univ Wisconsin, Med, Sch Med & Publ Hlth Med Phys, Madison, WI USA

[6] HuBei Canc Hosp, Med Dept, Wuhan, Peoples R China

[7] Sun Yat Sen Univ, Affiliated Hosp 6, Med, Guangzhou, Guangdong, Peoples R China

[8] Univ Colorado, Med Oncol Dept, UCHlth Canc Care, Ctr Canc, Anschutz Med Campus, Aurora, CO USA

[9] China Med Univ, Med, Affiliated Hosp 1, Shenyang, Peoples R China

[10] Horizon BioAdvance, Med Oncol Dept, Lafayette, LA USA

[11] Carolina BioOncol Inst, Oncol, Huntersville, NC USA

[12] UCI Univ Calif Irvine, Med Dept, Hlth Manchester Pavil, Orange, CA USA

[13] Mary Crowley Canc Res Ctr, Med Oncol Dept, Dallas, TX USA

[14] Rutgers Canc Inst New Jersey, Med Oncol Dept, New Brunswick, NJ USA

[15] Vanderbilt Univ, Med Dept, Med Ctr, Preston Canc Res Bldg, Nashville, TN USA

[16] NYU, Med Dept, Langone Laura & Isaac Perlmutter Canc Ctr, New York, NY USA

[17] I Mab Biopharma, Res & Dev, San Diego, CA USA

[18] I Mab Biopharma Co Ltd Headquarter, Res & Dev, Shanghai, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.2178

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1039P

引用

页码：S631 / S631

页数：1

共 50 条

[1] Updated safety and efficacy from the phase I study of givastomig, a novel claudin 18.2/4-1BB bispecific antibody, in claudin 18.2 positive advanced gastroesophageal carcinoma (GEC)
Klempner, S. J.
Shen, L.
Liu, D.
Dayyani, F.
Kratz, J.
Pan, H.
Liang, X.
Wang, Z.
Kim, S.
Deng, Y.
Deng, T.
Liu, T.
Girda, E.
Xu, C.
Nguyen, M. T.
Xia, J.
Wang, X.
Lee, S.
Jeon, J.
Ku, G. Y.
ANNALS OF ONCOLOGY, 2024, 35 : S689 - S689
[2] First-in-human phase I/II safety and preliminary efficacy of PM1032, a bispecific antibody targeting CLDN18.2 and 4-1BB, in patients with advanced solid tumors.
Guo, Ye
Wu, Lihua
Li, Yong
Wen, Jinhua
Xue, Junli
Wang, Zhuoyi
Li, Pu
Zhao, Wei
Liu, Jingfeng
Rao, Xi
Li, Qun
Xue, Liqiong
Ge, Xiaoxiao
Lin, Fengjuan
Tang, Wenbo
Zhou, Jiuli
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[3] A phase I/IIa first-in-human study of PM1003 (anti-PD-L1 x 4-1BB bispecific antibody) in patients with advanced solid tumors
Xue, J.
Sun, Y.
Li, D.
Guo, Y.
ANNALS OF ONCOLOGY, 2023, 34 : S629 - S629
[4] Claudin 18.2 X 4-1BB bispecific antibody induced potent tumor inhibition through tumor-specific 4-1BB activation
Jiang, Wenqing
Fang, Lei
Wang, Zhengyi
Guo, Taylor B.
Park, Eunyoung
Sung, Eunsil
Jung, Jaeho
CANCER RESEARCH, 2020, 80 (16)
[5] First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors
Hamid, Omid
Chiappori, Alberto A.
Thompson, John A.
Doi, Toshihiko
Hu-Lieskovan, Siwen
Eskens, Ferry A. L. M.
Ros, Willeke
Diab, Adi
Spano, Jean-Philippe
Rizvi, Naiyer A.
Wasser, Jeffrey S.
Angevin, Eric
Ott, Patrick A.
Forgie, Alison
Yang, Wenjing
Guo, Cen
Chou, Jeffrey
El-Khoueiry, Anthony B.
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (10)
[6] First-in-human, multicenter, open-label, phase I study of ATOR-1017 (evunzekibart), a 4-1BB antibody, in patients with advanced solid malignancies
Carneiro, Ana
Hahn, Amanda
Ellmark, Peter
Enell Smith, Karin
Schultz, Lena
Ambarkhane, Sumeet
Yachnin, Jeffrey
Ullenhag, Gustav J.
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2025, 13 (01)
[7] A first-in-human, multicenter, open-label, phase 1 study of ATOR-1017, a 4-1BB antibody, in patients with advanced solid malignancies.
Ullenhag, Gustav J.
Yachnin, Jeffrey
Carneiro, Ana
Elison, Emma
Carlsson, Malin
Russell, Charlotte Astrid
Smith, Karin Enell
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[8] Phase 1 trial safety and efficacy of ragistomig, a bispecific antibody targeting PD-L1 and 4-1BB, in advanced solid tumors
Falchook, Gerald Steven
LoRusso, Patricia
Goldman, Jonathan W.
El-Khoueiry, Anthony B.
Tolcher, Anthony W.
Xing, Yan
Henry, Jason Timothy
Keam, Bhumsuk
Kim, Dong-Wan
Kim, Tae-Yong
Kim, Hye Ryun
Hong, Min Hee
Kim, Min Hwan
Lee, Dae Ho
Lee, SangMi
Jeon, JuYeun
Hayslip, John W.
Xu, Cong
Garon, Edward B.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[9] Phase I safety and preliminary efficacy of PM1003, a bispecific antibody targeting PD-L1 and 4-1BB, in patients with advanced solid tumors
Xue, Junli
Sun, Yuping
Li, DaPeng
Guo, Ye
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[10] Development of a novel MSLN x 4-1BB bispecific antibody
Li, Liangwei
Zhang, Dayan
Shen, Guodong
Liu, Wenting
Zeng, Xiaoli
Wu, Lingling
Zhao, Qun
Zhou, Weiming
Huang, Yang
Cheng, Liansheng
CANCER RESEARCH, 2023, 83 (07)

← 1 2 3 4 5 →